NovoCure Ltd — Director's Dealing 2020

Feb 28, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2020-02-25

Reporting Person: Shah Pritesh (Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-02-25	Ordinary Shares	S	5067	$81.156	Disposed	75653	Direct
2020-02-26	Ordinary Shares	S	2100	$78.678	Disposed	73553	Direct
2020-02-26	Ordinary Shares	S	4332	$79.449	Disposed	69221	Direct
2020-02-26	Ordinary Shares	S	1500	$80.219	Disposed	67721	Direct

Footnotes

F1: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Shah.

F2: On February 26, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah, Mr. Shah sold 2100 shares in multiple trades at prices ranging from $77.97 to $78.94. The price reported above reflects the weighted average sale price. Mr. Shah hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.

F3: On February 26, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah, Mr. Shah sold 4332 shares in multiple trades at prices ranging from $79.00 to $79.99. The price reported above reflects the weighted average sale price. Mr. Shah hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.

F4: On February 26, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah, Mr. Shah sold 1500 shares in multiple trades at prices ranging from $80.01 to $80.51. The price reported above reflects the weighted average sale price. Mr. Shah hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.